Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly Gets Breakthrough Therapy Designation for Alzheimer's Treatment From FDA

06/24/2021 | 07:14am EDT

By Dave Sebastian

Eli Lilly & Co. said it has received breakthrough therapy designation for its Alzheimer's treatment from the U.S. Food and Drug Administration.

The designation means preliminary clinical evidence indicates the drug could show substantial improvement over available therapies on a clinically significant endpoint, and is meant to expedite the development and review of drugs for serious conditions, according to the FDA.

Lilly on Thursday said it plans to submit a biologics license application for the drug, donanemab, under the accelerated approval path later this year based on data from its Phase 2 trial. It said the safety, tolerability and efficacy of donanemab are being evaluated in an ongoing Phase 3 study.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

06-24-21 0713ET

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL 0.78% 35064.25 Delayed Quote.14.74%
ELI LILLY AND COMPANY 0.66% 264.19 Delayed Quote.55.45%
All news about ELI LILLY AND COMPANY
03:55pINSIDER TRENDS : Eli Lilly Insider Extends 90-Day Selling Trend
MT
12:29pELI LILLY AND : Morgan Stanley Adjusts Price Target on Eli Lilly to $275 From $2..
MT
09:26aToday on Wall Street: Unemployment benefits claims continue to fall
07:09aELI LILLY AND : DZ Bank Upgrades Eli Lilly to Buy From Hold; Price Target is $28..
MT
06:13aANALYST RECOMMENDATIONS : Barclays, Domino's Pizza, Eli Lilly, Experian, Walmart..
08/04INSIDER TRENDS : Eli Lilly Insider Continues 90-Day Selling Trend
MT
08/04BAJAJ HEALTHCARE : Files Compulsory License With Indian Patent Office For Barici..
AQ
08/04ELI LILLY AND : Goldman Sachs Adjusts Price Target for Eli Lilly and Company to ..
MT
08/04ELI LILLY AND : JPMorgan Adjusts Price Target for Eli Lilly and Company to $300 ..
MT
08/04ELI LILLY AND : Mizuho Securities Adjusts Eli Lilly's Price Target to $279 From ..
MT
More news
Financials (USD)
Sales 2021 27 169 M - -
Net income 2021 6 368 M - -
Net Debt 2021 11 369 M - -
P/E ratio 2021 37,9x
Yield 2021 1,25%
Capitalization 240 B 240 B -
EV / Sales 2021 9,23x
EV / Sales 2022 8,93x
Nbr of Employees 35 000
Free-Float 99,0%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 264,22 $
Average target price 253,90 $
Spread / Average Target -3,91%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY55.45%237 950
JOHNSON & JOHNSON10.15%456 367
ROCHE HOLDING AG14.56%340 460
PFIZER, INC.22.77%252 960
NOVARTIS AG-0.36%223 613
NOVO NORDISK A/S43.21%222 926